Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
A well-chosen CDx development partner can streamline drug development, reduce delays, and pave the way for successful regulatory approval and market entry.
For rare and inherited kidney diseases, genetic testing is solving the clinical trial recruitment crisis and reshaping how precision therapies get to patients.
Simtra is positioned to become the first CDMO to offer commercial-scale drug product manufacturing of ADCs in the US, enabling customers to complete the entire supply chain domestically.
Metabolic conditioning is emerging as a powerful strategy to enhance the potency, persistence, and manufacturability of next-generation cell therapies, providing new hope for hard to treat cancers.
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.